Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{152362,
        author = {Anjum F. Saudagar and Dhanraj N. Wasmate and Shyamlila B. Bavage and Nandkishor B. Bavage},
        title = {CLOZAPINE IN TREATMENT OF SCHIZOPHRENIA},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {8},
        number = {3},
        pages = {12-19},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=152362},
        abstract = {Clozapine is antipsychotic mediation which is mostly used in patients with treatment resistant schizophrenia and against the negative symptoms .In it the clinical response of 84 schizophrenic patients were examined, previous antipsychotic medication had been withdrawn, and patient were treated with clozapine according to standardization titration, we also observe the adverse effects, extrapyramidal symptoms , baseline pathology and literature of reviews. After all, these variables may have important for the use if clozapine and our understanding of the pathophysiology if treatment resistant – schizophrenia. },
        keywords = {Antipsychotic, Schizophrenia, Extrapyramidal symptoms, adverse effect and Baseline pathology.},
        month = {},
        }